Cerebellar ataxia is one of the most frequent syndromes associated with autoantibodies against glutamic acid decarboxylase (GAD-ab). Antibodies recognize the isoform GAD65, which is the standard biomarker, but additional immunoreactivity against GAD67 is found in high proportion of patients with GAD-ab-associated neurological disorders. We describe the case of a 59-year-old woman who presented with pancerebellar syndrome of subacute onset (9 weeks to nadir). In the etiological study, high titers of GAD-ab were found, but these only recognized the GAD67 isoform and not the GAD65. Screening of GAD67-ab should be considered in late-onset cerebellar ataxia when GAD65-ab are absent.
Introduction
Autoantibodies against glutamic acid decarboxylase (GAD-ab) associate with several neurologic disorders such as stiff-person syndrome, cerebellar ataxia, and limbic encephalitis (Saiz et al., 2008) . GAD-ab recognize the smaller isoform of the enzyme, GAD65, localized at the intracellular presynaptic site of inhibitory synapses, and high titers of GAD65-ab are currently a biomarker of these disorders. The presence of antibodies against the larger isoform, GAD67, is rarely included in clinical testing despite it has been reported in a high proportion of patients with GAD-ab associated disorders, usually accompanying GAD65-ab (Meinck et al., 2001) . It is unknown whether GAD67-ab alone associate with a specific neurological syndrome. We report here the case of a patient who developed cerebellar ataxia along with autoantibodies restricted to the GAD67 isoform.
Case report
In November 2015, a 59-year-old woman presented with sudden onset of dizziness, vomiting and vertigo for 15 days. She denied sensory deficits and other focal neurologic or systemic symptoms, but complained of blurred vision. Neurological examination was remarkable for vertical nystagmus, horizontal diplopia, and mild right-arm dysmetria on finger-to-nose testing. Routine laboratory evaluation, brain MRI and MR-angiography were normal (Fig. 1) . She was first treated for vertigo with betahistine and sulpiride, but during the ensuing 9 weeks she had a rapidly progressive neurological deterioration evolving to a pancerebellar syndrome. At examination, she had nystagmus on upward gaze, scanning speech, asymmetric dysmetria involving the 4 limbs, intention tremor, hypotonia, brisk deep tendon reflexes, right ankle clonus, and wide-based ataxic gait requiring bilateral assistance to walk. Cognition was normal. There were no other cranial nerve deficits, and she had normal strength. The score in ICARS scale was 61/100 (Trouillas et al., 1997) .
Repeat brain MRI was normal (Fig. 1) . Blood tests including blood count and renal function were normal. Specific studies for metabolic or nutritional deficits (copper, thyroid function, vitamins E and B12), autoimmune or inflammatory disorders (transglutaminase antibodies, antinuclear and Ro antibodies, angiotensin-converting enzyme) and tumor markers were unremarkable. Whole-body CT scan was normal. Two CSF studies were normal except for a CSF-restricted IgG oligoclonal band. Neuronal antibody studies using frozen rat brain tissue immunohistochemistry revealed a pattern of reactivity suggestive of GAD-ab in CSF and serum (Fig. 2) . Immunoblot using 2 commercial kits containing GAD65 (Euroimmune and Ravo) were both negative in serum and CSF. Serum was also negative for GAD65 using a commercial RIA analysis. An 
